drugset / Trial / NCT02342353
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of the study is to find the best dose of pacritinib when given in combination with erlotinib.
Timeline
- Start
- 2015-05-18
- Primary completion
- 2018-02-06
- Completion
- 2018-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Pacritinib | Small molecule | — | Oral |